Plinabulin demonstrated similar efficacy to pegfilgrastim for the prevention of chemotherapy-induced neutropenia, according to results of a randomized phase 3 study published in JAMA Network Open.
“Plinabulin, a nongranulocyte colony-stimulating factor agent that has anticancer properties, was shown to reduce the incidence of chemotherapy-induced neutropenia in a phase 2 clinical trial including patients with lung cancer,” Douglas W. Blayney, MD, professor of medicine at Stanford Cancer Institute, told Healio. “We conducted a separate phase 2 clinical trial that had more